Putative Mechanism | Treatment | Fold Induction2-a | Phase I Gene2-b |
---|---|---|---|
AhR | TCDD | 693 | CYP1A1 |
I3C | 6.7 | ||
BNF | 511 | ||
PCB126 | 456 | ||
CAR | PB | 54.2 | CYP2B1/2 |
PCB99 | 76.3 | ||
DAS | 96.7 | ||
PXR | PCN | 16.1 | CYP3A1/23 |
Spir | 14.0 | ||
Dex | 32.9 | ||
PPAR | Clof | 4.6 | CYP4A2/3 |
DEHP | 9.2 | ||
PFDA | 6.7 | ||
ARE/EpRE | EQ | 3.6 | QR |
Olt | 5.4 | ||
INH | 1.4 | CYP2E1 | |
ASA | 1.2 | ||
Strep | 1.9 |
AhR, aryl-hydrocarbon receptor; PXR, pregnane-X receptor; PPAR, peroxisome proliferator activator receptor; ARE/EpRE, antioxidant response element/electrophile response element; I3C, indole-3-carbinol; BNF, β-naphthoflavone; DAS, diallyl sulfide; Spir, spironolactone; Dex, dexamethasone; Clof, clofibric acid; DEHP, diethylhexylphthalate; PFDA, perfluorodecanoic acid; EQ, ethoxyquin; Olt, oltipraz; INH, isoniazid; ASA, acetylsalicylic acid; Strep, streptozotocin.
↵2-a Single determination of pooled total RNA (n = 5) divided by the average of the three control groups (corn oil ip, po and saline ip).
↵2-b Refers to the gene transcript that was measured to demonstrate that each treatment induced appropriately.